PHIO PHARMACEUTICALS CORP (PHIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.08-2.70%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Cash from operations remains above -$4.0 million: OCF -8.8M vs -4.0M.
Phio aims to manage losses and negative cash flow. It plans to improve operations. The company has a new $21.3 million funding target for mid-2027. Recent earnings beats show some progress.
Phio's losses are growing, with operating income down to -$4.17 million. Earnings estimates keep falling. The company remains unprofitable and cash flow is negative.
The market prices in continued losses and negative earnings. Our view sees risk in worsening losses and cash flow.
Breaks if: Cash from operations falls below -$4.0 million in 2026-Q1
Control operating expenses and cash burn while advancing clinical programs to manage net losses and negative cash flow.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth bet, as PHIO is focused on advancing its clinical programs while facing significant operating losses. The current thesis state is cautious, with recent financial performance being weak and management navigating high risks.
The market appears to have priced in the challenges of being a loss-making company, with expectations for continued operating losses and cash management. There is a sense of caution given the recent earnings miss and the company's weak financial performance compared to its peers.
Fundamentals are likely to remain under pressure in the near term, as management continues to manage operating losses while advancing clinical development. The recent increase in company momentum may provide some support, but the overall financial performance remains weak.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. Net loss increased slightly from $4.0 million in 2026-Q1 to $4.1 million in 2026-Q2, driven by rising R&D expenses advancing PH-762. General and administrative expenses were managed with minor fluctuations. The trajectory shows ongoing operating losses consistent with advancing clinical programs and managing expenses prudently.
“R&D expenses increased to $3.1 million; net loss $4.1 million; G&A expenses managed prudently.”
“R&D expenses $2.8 million; net loss $4.0 million; G&A expenses increased due to employee and investor outreach costs.”
Breaks if: Net income falls below -$4.0 million in 2026-Q1
Control operating expenses and cash burn while advancing clinical programs to manage net losses and negative cash flow.
Stated as a priority in 2 of last 2 quarters. Net loss increased slightly from $4.0 million in 2026-Q1 to $4.1 million in 2026-Q2, driven by rising R&D expenses advancing PH-762. General and administrative expenses were managed with minor fluctuations. The trajectory shows ongoing operating losses consistent with advancing clinical programs and managing expenses prudently.
“R&D expenses increased to $3.1 million; net loss $4.1 million; G&A expenses managed prudently.”
“R&D expenses $2.8 million; net loss $4.0 million; G&A expenses increased due to employee and investor outreach costs.”
Breaks if: Operating income falls below -$4.17 million in 2026-Q1
Control operating expenses and cash burn while advancing clinical programs to manage net losses and negative cash flow.
Stated as a priority in 2 of last 2 quarters. Net loss increased slightly from $4.0 million in 2026-Q1 to $4.1 million in 2026-Q2, driven by rising R&D expenses advancing PH-762. General and administrative expenses were managed with minor fluctuations. The trajectory shows ongoing operating losses consistent with advancing clinical programs and managing expenses prudently.
“R&D expenses increased to $3.1 million; net loss $4.1 million; G&A expenses managed prudently.”
“R&D expenses $2.8 million; net loss $4.0 million; G&A expenses increased due to employee and investor outreach costs.”
Breaks if: Funding falls short of $21.3 million by mid-2027
The thesis hinges on several factors, including the outcome of upcoming earnings guidance and the performance of sector bellwethers like VRTX, REGN, and ARGX. Additionally, broader economic indicators, such as the jobs report, could significantly impact investor sentiment and stock performance.
In the next 1 to 3 years, PHIO's prospects will depend heavily on its clinical development progress and the overall health of the healthcare sector. Not investment advice.